Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

NCT06087068 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer
Surgery
Recurrence

Interventions

DRUG: Thyroxine

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences